Funding Opportunities & Resources

New Opportunities
Below are the recently released Fiscal Year 2024 (FY24) pre-announcements for Department of Defense (DOD) programs managed by the Congressionally Directed Medical Research Programs (CDMRP).

 

The FY24 Defense Appropriations Bill has not been signed into law. Although FY24 funds have not been appropriated, CDMRP is providing the information in the following pre-announcements to allow investigators time to plan and develop ideas for submission to anticipated FY24 funding opportunities. These pre-annoucements should not be construed as an obligation by the government.

 

FY24 pre-announcements released:
The Melanoma Research Program (MRP) released a pre-announcement for the following anticipated funding opportunities:

·        Survivorship and Patient Wellness Research Award **NEW for FY24!**

·        Focused Program Award – Rare Melanomas

·        Idea Award

·        Melanoma Academy Scholar Award

·        Team Science Award

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24mrppreann
The Prostate Cancer Research Program (PCRP) released a pre-announcement for the following anticipated funding opportunities:

·        Implementation Science Award **NEW for FY24!**

·        Data Science Award

·        Early Investigator Research Award

·        Exploration-Hypothesis Development Award

·        Idea Development Award

·        Physician Research Award

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24pcrppreann
The FY24 Spinal Cord Injury Research Program (SCIRP) released a pre-announcement for the following funding opportunities:

·        Clinical Trial Award

·        Clinical Translation Research Award

·        Translational Research Award

·        Investigator-Initiated Research Award

Early-Career Partnering Principal Investigator (PI) Option:  For all FY24 SCIRP funding opportunities, the program anticipates continuing to offer an Early Career Partnering PI option in an effort to promote enhanced research capacity within the SCI field.  This option is structured to accommodate two PIs who will work together on a single research project, but each will be named to separate individual awards within the recipient organization(s).  To exercise this option, at least one of the PIs must be an early-career investigator with at least 3 years research experience (independent or non-independent) beyond a terminal degree but no more than 7 years within their first faculty appointment, or equivalent independent research position.  Applications that employ the Early Career Partnering PI option are subject to a larger direct cost maximum and may divide budgetary costs across the two awards as appropriate for their separate efforts toward the research project proposed.

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24scirppreann
The Traumatic Brain Injury and Psychological Health Research Program has released a pre-announcement for the following anticipated funding opportunities:

·        Clinical Trial Award

·        Emerging Research Award *New for FY24

·        Focused Program Award

·        Health Services Research Award

·        Translational Research Award

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24tbiphrppreann
The FY24 Peer Reviewed Orthopaedic Research Program (PRORP) released a pre-announcement for the following funding opportunities:

·        Applied Research Award

·        Clinical Translational Research Award

·        Clinical Trial Award

·        Women’s Health Research Award *New for F24*

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24prorppreann
The FY24 Tick-Borne Disease Research Program (TBDRP) released a pre-announcement for the following funding opportunities:

·        Idea Development Award

·        Therapeutic/Diagnostic Research Award

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24tbdrppreann
03/07/2024 Notice: The Military Burn Research Program released a pre-announcement for the following funding opportunities:

·        Patient-Centered Research Award

·        Technology/Therapeutic Development Award

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24mbrppreann
03/07/2024 Notice: The Multiple Sclerosis Research Program released a pre-announcement for the following funding opportunities:

·        Clinical Trial Award

·        Early Investigator Research Award

·        Exploration – Hypothesis Development Award – New Investigator Option

·        Investigator – Initiated Research Award – New Investigator Option

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24msrppreann
03/07/2024 Notice: The Pancreatic Cancer Research Program released a pre-announcement for the following funding opportunities:

·        Focused Pilot Award

·        Idea Development Award

·        Idea Development Award – Early Career Investigator Option

·        Translational Research Partnership Award

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24pcarppreann
03/26/2024 Notice: The Peer Reviewed Cancer Research Program (PRCRP) released a pre-announcement for the following funding opportunities:

·        Advancing Clinical Care Through Clinical Trials Award

·        Career Development Award – Scholar Option

·        Convergent Science Cancer Consortium Award

·        Idea Award

·        Impact Award

·        Patient Well-Being and Survivorship Award

·        Virtual Cancer Center Director Award

 

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2024/24prcrppreann
Regeneron Pharmaceuticals is seeking VA sites for its study, A Phase 3 Study Of Fixed Dose Combinations Of Fianlimab And Cemiplimab Versus Relatlimab And Nivolumab In Participants With Unresectable Or Metastatic Melanoma.

 

If you are interested in pursuing this study, please contact Chris Isibor at [email protected].
Regeneron Pharmaceuticals is seeking VA sites for its study, A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Patients with Early Stage Cutaneous Squamous Cell Carcinoma (CSCC).

 

If you are interested in pursuing this study, please contact Chris Isibor at [email protected].
Abbvie is seeking VA sites for its study trial Chronic Lymphocytic Leukemia Venetoclax initiation study.

 

Study Targets:

·        First Subject Dose: 26 June 2024

·        Last Subject Off: 26 February 2026

·        Planned number of sites: 230

·        Planned number of Subjects Enrolled: 620

·        Study-level enrollment rate assumption: 0.4 subjects/site/month

 

If you are interested in pursuing this study, please contact Ernestine Favors at [email protected].
Parexel is seeking VA sites for a Hookipa Pharma study, Phase 2/3 Clinical Study for Recurrent and/or Metastatic Oropharyngeal Squamous Cell Carcinoma that is HPV16+ and PD-L1 CPS ≥ 20. They aren’t quite ready to send out feasibility questionnaires yet, but would like to gauge your interest and collect potential PI names.

 

If you are interested in pursuing this study, please contact Nikki Giardina at [email protected].
03/28/2024 Notice: The Breast Cancer Research Program (BCRP) released program announcements for the following funding opportunities:

·        Breakthrough Award Levels 1 and 2

·        Breakthrough Award Levels 3

·        Breakthrough Award Levels 4

·        Clinical Research Extension Award

·        Era of Hope Scholar Award

·        Transformative Breast Cancer Consortium Award

·        Transformative Breast Cancer Consortium Development Award

 

While the Breakthrough Award Level 3, Breakthrough Award Level 4, and Transformative Breast Cancer Consortium Award mechanisms were released twice per fiscal year during recent years, it is anticipated that these three mechanisms will be released once for FY24. If interested in applying to these three FY24 mechanisms, investigators are strongly encouraged to apply to the current funding opportunities for which pre-applications are due 14 May 2024.

 

To view the program announcements and submit a pre-application, visit https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=573101
03/28/2024 Notice: The Lung Cancer Research Program (LCRP) released program announcements for the following funding opportunities:

·        Concept Award

·        Career Development Award

·        Idea Development Award

·        Translational Research Award

·        Patient-Centered Outcomes and Survivorship Award

 

To view the program announcements and submit a pre-application, visit https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=583102
03/28/2024 Notice: The Ovarian Cancer Research Program (OCRP) released program announcements for the following funding opportunities:

·        Pilot Award

·        Investigator-Initiated Research Award

·        Clinical Trial Award

·        Clinical Trial Translational Endpoints Research Award * * (NEW)

·        Ovarian Cancer Academy – Leadership Award

·        Ovarian Cancer Academy – Early-Career Investigator Award

 

To view the program announcements and submit a pre-application, visit https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=581101
Explore Funding
NIH Resources
VA Links

·        VA Eastern Colorado Health Care System: Public website for VAECHCS

·        VAECHCS Research: Public website for VAECHCS Research

·        Office of Research & Development (ORD): Public website for National VA R&D Office

·        Office of Research Oversight: VA’s National Office of Research Oversight (ORO)

A black background with red, white and blue letters.

Get Involved! Would you like to get involved with your local Veteran’s Administration
through volunteering or research?

Follow Us

© 2022 DRI. All Rights Reserved. CREATED BY: DESIGN HEROES